Cargando…
Drug Interactions With New Synthetic Opioids
Fentanyl, fentanyl analogs, and other new synthetic opioids (NSO) have burst onto the illegal drug market as new psychoactive substances (NPS). They are often sold as heroin to unsuspecting users and produce euphoria through their agonist action on μ- opioid receptors. Their high consumption, often...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193107/ https://www.ncbi.nlm.nih.gov/pubmed/30364252 http://dx.doi.org/10.3389/fphar.2018.01145 |
_version_ | 1783364015874899968 |
---|---|
author | Pérez-Mañá, Clara Papaseit, Esther Fonseca, Francina Farré, Adriana Torrens, Marta Farré, Magi |
author_facet | Pérez-Mañá, Clara Papaseit, Esther Fonseca, Francina Farré, Adriana Torrens, Marta Farré, Magi |
author_sort | Pérez-Mañá, Clara |
collection | PubMed |
description | Fentanyl, fentanyl analogs, and other new synthetic opioids (NSO) have burst onto the illegal drug market as new psychoactive substances (NPS). They are often sold as heroin to unsuspecting users and produce euphoria through their agonist action on μ- opioid receptors. Their high consumption, often combined with other substances, has led to multiple intoxications during recent years. In some countries, such as the United States, the consumption of opioids, whether for medical or recreational purposes, has become epidemic and is considered a public health problem. Fentanyl analogs are more potent than fentanyl which in turn is 50 times more potent than morphine. Furthermore, some fentanyl analogs have longer duration of action and therefore interactions with other substances and medicines can be more serious. This review is focused on the potentially most frequent interactions of opioid NPS taking into account the drugs present in the reported cases of poly-intoxication, including other illegal drugs of abuse and medication. Substances involved are mainly antidepressants, antihistamines, antipsychotics, benzodiazepines, analgesics, anesthetics, psychostimulants, other opioids, alcohol, and illegal drugs of abuse. The interactions can be produced due to pharmacokinetic and pharmacodynamic mechanisms. Naloxone can be used as an antidote, although required doses might be higher than for traditional opioid intoxications. It is crucial that doctors who habitually prescribe opioids, which are often misused by patients and NPS users, be aware of designer opioids’ potentially life-threatening drug-drug interactions in order to prevent new cases of intoxication. |
format | Online Article Text |
id | pubmed-6193107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61931072018-10-25 Drug Interactions With New Synthetic Opioids Pérez-Mañá, Clara Papaseit, Esther Fonseca, Francina Farré, Adriana Torrens, Marta Farré, Magi Front Pharmacol Pharmacology Fentanyl, fentanyl analogs, and other new synthetic opioids (NSO) have burst onto the illegal drug market as new psychoactive substances (NPS). They are often sold as heroin to unsuspecting users and produce euphoria through their agonist action on μ- opioid receptors. Their high consumption, often combined with other substances, has led to multiple intoxications during recent years. In some countries, such as the United States, the consumption of opioids, whether for medical or recreational purposes, has become epidemic and is considered a public health problem. Fentanyl analogs are more potent than fentanyl which in turn is 50 times more potent than morphine. Furthermore, some fentanyl analogs have longer duration of action and therefore interactions with other substances and medicines can be more serious. This review is focused on the potentially most frequent interactions of opioid NPS taking into account the drugs present in the reported cases of poly-intoxication, including other illegal drugs of abuse and medication. Substances involved are mainly antidepressants, antihistamines, antipsychotics, benzodiazepines, analgesics, anesthetics, psychostimulants, other opioids, alcohol, and illegal drugs of abuse. The interactions can be produced due to pharmacokinetic and pharmacodynamic mechanisms. Naloxone can be used as an antidote, although required doses might be higher than for traditional opioid intoxications. It is crucial that doctors who habitually prescribe opioids, which are often misused by patients and NPS users, be aware of designer opioids’ potentially life-threatening drug-drug interactions in order to prevent new cases of intoxication. Frontiers Media S.A. 2018-10-11 /pmc/articles/PMC6193107/ /pubmed/30364252 http://dx.doi.org/10.3389/fphar.2018.01145 Text en Copyright © 2018 Pérez-Mañá, Papaseit, Fonseca, Farré, Torrens and Farré. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Pérez-Mañá, Clara Papaseit, Esther Fonseca, Francina Farré, Adriana Torrens, Marta Farré, Magi Drug Interactions With New Synthetic Opioids |
title | Drug Interactions With New Synthetic Opioids |
title_full | Drug Interactions With New Synthetic Opioids |
title_fullStr | Drug Interactions With New Synthetic Opioids |
title_full_unstemmed | Drug Interactions With New Synthetic Opioids |
title_short | Drug Interactions With New Synthetic Opioids |
title_sort | drug interactions with new synthetic opioids |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193107/ https://www.ncbi.nlm.nih.gov/pubmed/30364252 http://dx.doi.org/10.3389/fphar.2018.01145 |
work_keys_str_mv | AT perezmanaclara druginteractionswithnewsyntheticopioids AT papaseitesther druginteractionswithnewsyntheticopioids AT fonsecafrancina druginteractionswithnewsyntheticopioids AT farreadriana druginteractionswithnewsyntheticopioids AT torrensmarta druginteractionswithnewsyntheticopioids AT farremagi druginteractionswithnewsyntheticopioids |